Page last updated: 2024-09-04
evodiamine and gw9662
evodiamine has been researched along with gw9662 in 1 studies
Compound Research Comparison
| Studies (evodiamine) | Trials (evodiamine) | Recent Studies (post-2010) (evodiamine) | Studies (gw9662) | Trials (gw9662) | Recent Studies (post-2010) (gw9662) |
|---|---|---|---|---|---|
| 336 | 1 | 240 | 617 | 0 | 406 |
Protein Interaction Comparison
| Protein | Taxonomy | evodiamine (IC50) | gw9662 (IC50) |
|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 3.3 | |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | 0.086 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Dong, F; Liu, X; Luan, C; Luan, S; Shao, H; Sun, C; Zhang, G | 1 |
Other Studies
1 other study(ies) available for evodiamine and gw9662
| Article | Year |
|---|---|
Evodiamine inhibits the proliferation of leukemia cell line K562 by regulating peroxisome proliferators-activated receptor gamma (PPARγ) pathway.
Topics: Anilides; Apoptosis; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia; PPAR gamma; Quinazolines | 2016 |